Kcnq1, which encodes for the pore-forming a-subunit of a voltage-gated potassium channel, was identified as a gastrointestinal (GI) tract cancer susceptibility gene in multiple Sleeping Beauty DNA transposon-based forward genetic screens in mice. To confirm that Kcnq1 has a functional role in GI tract cancer, we created Apc Min mice that carried a targeted deletion mutation in Kcnq1. Results demonstrated that Kcnq1 is a tumor suppressor gene as Kcnq1 mutant mice developed significantly more intestinal tumors, especially in the proximal small intestine and colon, and some of these tumors progressed to become aggressive adenocarcinomas. Gross tissue abnormalities were also observed in the rectum, pancreas and stomach. Colon organoid formation was significantly increased in organoids created from Kcnq1 mutant mice compared with wild-type littermate controls, suggesting a role for Kcnq1 in the regulation of the intestinal crypt stem cell compartment. To identify gene expression changes due to loss of Kcnq1, we carried out microarray studies in the colon and proximal small intestine. We identified altered genes involved in innate immune responses, goblet and Paneth cell function, ion channels, intestinal stem cells, epidermal growth factor receptor and other growth regulatory signaling pathways. We also found genes implicated in inflammation and in cellular detoxification. Pathway analysis using Ingenuity Pathway Analysis and Gene Set Enrichment Analysis confirmed the importance of these gene clusters and further identified significant overlap with genes regulated by MUC2 and CFTR, two important regulators of intestinal homeostasis. To investigate the role of KCNQ1 in human colorectal cancer (CRC), we measured protein levels of KCNQ1 by immunohistochemistry in tissue microarrays containing samples from CRC patients with liver metastases who had undergone hepatic resection. Results showed that low expression of KCNQ1 expression was significantly associated with poor overall survival.
INTRODUCTION
The KCNQ1 gene encodes for the pore-forming a-subunit of a voltage-gated potassium channel that enables a K þ current after electrical depolarization of the cell membrane. KCNQ1 is predominantly expressed in the myocardium, inner ear, stomach, intestine and pancreas, tissues in which KCNQ1 expression is critical for ion homeostasis. 1 Inherited mutations in KCNQ1 underlie several human disease syndromes. For example, mutations in KCNQ1 are associated with congenital long QT syndrome, a disorder caused by abnormal ventricular repolarization that increases the risk of sudden death from cardiac arrhythmias. Jervell and Lange-Nielson syndrome is a rare autosomal disorder characterized by deafness in addition to long QT syndrome. Recent reports indicate that Jervell and Lange-Nielson syndrome patients can also be susceptible to GI defects, including iron-deficiency anemia, gastric and duodenal hyperplasia, elevated gastrin levels and, more rarely, gastric adenocarcinoma. [2] [3] [4] [5] Variants in KCNQ1 are also associated with enhanced risk for type 2 diabetes. 6, 7 Relatively little is known about the role of KCNQ1 in cancer, but a potential role in GI tract cancers was indicated by its identification as a high-frequency common insertion site locus in Sleeping Beauty DNA transposon-based forward mutagenesis genetic screens for intestinal 8, 9 and pancreatic cancer. 10, 11 In our forward genetic screen in Apc wild-type mice, we found Kcnq1 mutations in 18 intestinal tumors (13%), 8 ranking it among the top 10 common insertion site genes. In this study, while transposon insertions in Kcnq1 were found in tumors from all regions of the intestine, approximately two-thirds (64%) were located in the duodenum and jejunum, with 26% in the ileum and 10% in the colon. Furthermore, transposon insertions in Kcnq1 were observed equally in both the forward and reverse strand orientation, consistent with a model whereby the transposon is acting to disrupt gene function. We performed a second forward genetic screen in Apc Min mice and found Kcnq1 transposon insertions in 13 intestinal tumors (14%). 12 Another screen in Apc Min mice found Kcnq1 transposon mutations in 120 intestinal tumors (27%), ranking it no. 15 out of 641 common insertion site genes (120 kb window). 9 We have also conducted a screen using p53 R270H mutant mice and identified insertions in Kcnq1 in 15 intestinal tumors (23%) (TK Starr, personal communication).
Six mutant mouse alleles of Kcnq1 have been created that partially model human disorders arising from inherited mutations in KCNQ1, especially Jervell and Lange-Nielson syndrome. [13] [14] [15] [16] [17] These mutant alleles share similar but not identical phenotypes, including bilateral deafness from birth, gastric hyperplasia, gastric achlorhydria, elevated serum gastrin, headbobbing, bidirectional circling, ataxia, body tremor and hyperactivity with a consequent significant decrease in body weight. Conflicting results were reported regarding a cardiac phenotype in these models. In mouse small intestine, Kcnq1 expression is strongest in the duodenum and proximal jejunum and decreases towards the ileum. 18, 19 In the large intestine, Kcnq1 expression is strongest in the distal colon. 20, 21 To further investigate the role of Kcnq1 in GI tract cancers, we measured GI cancer phenotypes following introgression of a targeted knockout (KO) allele of Kcnq1 14 into the Apc Min model of intestinal tumorigenesis. We then investigated the role of KCNQ1 in progression of human colorectal cancer (CRC) by measuring KCNQ1 protein levels in tissue microarrays containing samples from more than 500 CRC patients with liver metastases. Results from both of these studies indicate that Kcnq1 is a tumor suppressor.
RESULTS
Loss of Kcnq1 enhances tumor multiplicity in Apc Min mice Haploinsufficiency for Kcnq1 significantly enhanced Apc Min intestinal tumor multiplicity overall, in both males and females, byB40% (Table 1) , with the phenotype strongest in the proximal small intestine and colon, where tumors increased B2-fold. Kcnq1 À / À mice in our study manifested a range of previously reported phenotypes: rapid bidirectional circling, ataxia, tremor, head bobbing and they were smaller (Bk25%, body weight) and leaner than littermate Kcnq1 wild-type and heterozygous mice. Less than half of the expected number of Apc Min Kcnq1 À / À mice survived until weaning (23 vs B60). Survivor Apc Min Kcnq1 / À mice demonstrated a very strong increase in tumors in the proximal half of the small intestine (B3-fold), especially in the proximal quarter of the small intestine containing the duodenum and proximal jejunum (Table 2) , the region exhibiting strongest expression of Kcnq1 in the intestine. Apc Min Kcnq1 À / À mice developed B2-fold increase in colon tumors but no increase in the distal small intestine of males, and a decrease in females. No significant differences between Kcnq1 genotypes in tumor sizes were observed.
Loss of Kcnq1 promotes tumor progression
Tumors in Apc Min mice are invariably benign adenomas that usually vary in size between 0.3 and B5 mm. Adenocarcinomas are extremely rare. In Apc Min mice carrying either heterozygous or homozygous mutations in Kcnq1 development of adenocarcinomas occurred at a frequency of B10-15%. These adenocarcinomas appeared as large lesions (some 420 mm), located in the proximal small intestine in a region approximate with the duodenal-jejunal flexure at the head of the pancreas. In almost all cases, there was buckling of the intestinal tube, in two cases there was a pronounced intussusception of the tissue and in two cases the tumors extended across the entire inner surface of the intestinal lumen. Six of these large tumors were analyzed by histopathology and all were found to be invasive adenocarcinomas ( Figure 1 ). Figure 1a depicts a lesion of 42 cm in length from the duodenum of an Apc Min Kcnq1 þ / À mouse, which when sectioned regionally revealed adenocarcinoma tissue in each section. No adenocarcinomas were detected in the remainder of the small intestine or in the large intestine, and no putative adenocarcinomas were detected in Apc Min -Kcnq1 þ / þ mice.
Loss of Kcnq1 is associated with other pathologies in the GI tract Rectal prolapse was evident in B10% of Apc Min Kcnq1 þ / À and Apc Min Kcnq1 À / À mice and in several cases the rectal prolapses were associated with enlarged rectums characterized by diffuse severe crypt hyperplasia ( Supplementary Figure 1 ). In addition, Kcnq1 À / À mice developed severe gastric hyperplasia that was characterized by mucosal hyperplasia, with parietal cells increased in size and crypt dilation with extensive cellular debris (Supplementary Figure 2 ). Hyperplastic adenomas in the pylorus were also present in Apc Min Kcnq1 mutant mice. Although Apc Min Kcnq1 þ / À mice showed an incidence of pyloric tumors of B30%, the phenotype was much stronger in Apc Min Kcnq1 À / À mice where the incidence of pyloric tumors was 490% (21/23). Furthermore, in Apc Min Kcnq1 À / À mice pyloric tumor multiplicity was much larger, with some mice developing as many as a dozen tumors. No pyloric tumors were observed in Apc Min Kcnq1 þ / þ mice. Finally, roughly one-third of Apc Min Kcnq1 À / À mice developed grossly and severely enlarged (B2-to 3-fold) pancreases, characterized by extra lobes. Histopathology of a matched pair of samples indicated that zymogen granules were less eosinophilic and less prominent, and that both exocrine cells and islets were smaller (Supplementary Figure 3 ).
Loss of Kcnq1 has a strong effect on gene expression
We conducted cDNA microarray expression studies using tissue from distal colon and the proximal quarter of the small intestine of Apc þ / þ Kcnq1 À / À and Apc þ / þ Kcnq1 þ / þ mice. Overall, more than 400 genes showed a 41.5-fold change in expression, and 4200 of these genes also had a P-value of o0.05 (Supplementary Tables 1 and 2). Expression of 20 genes was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) (Figures 2 and  3 ). Target genes were clustered into several functional groups: innate immune response/goblet and Paneth cell function (Ang4, Retnlb, Clps, Pnliprp2, Clca3, Muc2, Reg3a, Reg3b, Reg3g, Car1), ion channels (Trpv6, Slc12a8, Slc30a10, Aqp7, Aqp1, Aqp8, Aqp4, Clca3, Clca6), mucins (Muc2, Muc13, Muc4, Muc3), growth regulatory signaling pathways (Areg, Egr1, Fos, Ccdn1), cancer cell migration (Mmp9, Mmp15, S100a14, Mt1), apoptosis (Casp14, Casp2, Bcl6), Abbreviation: SI, small intestine. Apc Min Kcnq1 þ / þ , Apc Min Kcnq1 þ / À and Apc Min Kcnq1 À / À mice were killed at 120 days of age and tumors counted and measured. *P-values: o0.05; two-sided P-values for tumor counts were determined by use of the Wilcoxon rank-sum test comparing gender-and age-matched classes produced in the same genetic crosses. Table 2 . Apc Min Kcnq1 À / À tumor phenotype is strongest in the proximal quarter of the small intestine
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Mice and tissues are the same as inflammation, mediated by mechanisms such as detoxification and stress responses (Cyp2c55, Gstk1, Sirt1, Sirt3, Aldh1a1, Aldh1b1, Aldh2, Mt1, Gstm2), the adaptive immune response and intestinal stem cell-related genes (Clca4, Aqp4, Aldh1a1, Olfm4), consistent with a role for Kcnq1 in the intestinal stem cell compartment. 22 Interestingly, while loss of Kcnq1 showed a strong effect on colon secretory cell genes, there was no change in colon tissues in the secretory cell populations or cell proliferation (Supplementary Figure 4 ).
Kcnq1, Cftr and Muc2 share common genetic pathways in the GI tract Ingenuity Pathway Analysis (IPA) 23 identified significant networks and functional groups altered in Kcnq1 KO mice (see Supplementary Figures 5A and B and Supplementary Table 3 (colon) and Supplementary Figure 6 and Supplementary Table 4 (proximal small intestine). In particular, IPA analysis identified Cftr as a top upstream regulator of Kcnq1 KO dysregulated genes, indicating that genes differentially expressed in the Kcnq1 KO mice overlap with targets of Cftr (overlap P-value of 5.81E À 13, activation Z-score À 2.722). Furthermore, the Cftr network is predicted to be downregulated in Kcnq1 KO small intestine, suggesting that Kcnq1 may be necessary for some aspects of Cftr function. To identify common pathways and genes disrupted by Kcnq1 and Cftr deficiencies, we used Gene Set Enrichment Analysis (GSEA). 24 The entire ranked expression data set from the Kcnq1 KO proximal small intestine array was compared with gene sets compiled from a microarray analysis of gene expression in the small intestine of Cftr KO mice. 25 Cftr gene sets consisted of all genes up-or downregulated by twofold in the Cftr KO mouse. GSEA revealed significant correlation, with overlap of gene identity and direction of regulation (Figure 4 and Supplementary  Table 5 ; normalized enrichment score (NES) for Cftr KO upregulated genes 1.97, Po0.001; NES for Cftr KO downregulated genes À 1.92, Po0.001).
These shared targets included a large subset of genes involved in lipid metabolism and, in particular, downregulation of genes involved in lipid oxidation. In support of the significance of this overlap, IPA analyses of Kcnq1 KO and Cftr KO mice each identified lipid metabolism as a major functional category, with oxidation of lipids as the subcategory showing the most significant down regulation (Kcnq1, P-value 9.78E À 06, activation Z-score, À 2.26; Cftr, P-value 9.37E À 09, Z-score, À 3.62). Common targets included upregulation of Idi1, involved in cholesterol synthesis, and downregulation of Hsd174b and Acaa1b, both involved in fatty acid beta oxidation. Inhibition of fatty acid oxidation is associated with a switch to lipogenesis and this switch is characteristic of metabolic remodeling that commonly occurs during oncogenesis. 26 Also, fatty acid metabolism has recently been shown to have a key role in stem cell maintenance with lipogenesis associated with more highly proliferating stem cells. 27 Thus, altered lipid metabolism may contribute to the development of CRC in Kcnq1 and Cftr KO mice.
A second group of genes dysregulated in both Kcnq1 KO mice and Cftr KO mice is involved in inflammation. Because the intestinal epithelium is constantly exposed to flora and foreign substances, it must maintain protective and repair mechanisms. Disruption of these protective or homeostatic processes can result in inflammatory changes, which in turn are associated with inflammatory bowel disease and increased risk of CRC. 28 Genes involved in inflammation are dysregulated in both Kcnq1 KO mice and Cftr KO mice. These include upregulation of factors normally produced by intestinal epithelial cells to maintain immune homeostasis, including Il7, 29 Reg3g 30 and Pglryp1. 31 In addition, a number of protective genes are downregulated including those involved in detoxification, Gstt1, Cyp3a11, Cyp2b10, and others involved in protective signaling, such as Sema7a, which promotes Il10 signaling, 32 and Ace2, which protects against inflammationinduced epithelial damage. 33 Further evidence of overlap between KCNQ1 and CFTR was provided by analyzing RNA Seq data from 20 CRC liver metastases samples for concordance between expression levels of each gene. Using Pearson's correlation analysis of FPKM (fragments per kilobase pair of exon model per million fragments mapped) values in the 20 samples, it was found that KCNQ1 and CFTR were significantly coexpressed, despite up to a 10-fold sample-to-sample FPKM variability for each gene (see Supplementary Figures 7A and B ). Finally, both KCNQ1 and CFTR are regulated downstream of the serine threonine kinase gene SGK1, which is activated by factors including insulin, via the PI3K pathway, under conditions of osmotic stress. 34 SGK1 levels in turn appear to be influenced by the activity of both KCNQ1 and CFTR, as Sgk1 expression was upregulated by more than twofold in Kcnq1 KO colon (Supplementary Table 1 ) and was also upregulated by 41.6-fold in Cftr KO colon (BLN Than, personal communication). Of further interest, Sgk1 expression levels were downregulated by 1.5-fold in the proximal small intestine of Kcnq1 KO mice and downregulated by 5.5-fold in the small intestine of Cftr KO mice. 25 CFTR export of Cl À and HCO3 À maintains extracellular H 2 O homeostasis, which in turn is necessary for hydration and function of the protective lumenal mucin layer. 35 Another gene directly involved in maintenance of the mucin layer is MUC2, which encodes MUCIN2, one of the major glycoproteins making up this layer. As with Kcnq1 and Cftr, Muc2 deficiency is implicated in CRC. 36 To test if common pathways were disrupted by loss of Kcnq1 and Muc2, we compared gene expression changes in the Kcnq1 KO mouse with those reported for Muc2 KO mice. 36 GSEA identified significant overlap in gene expression, with genes downregulated in Muc2 KO mice enriched in genes downregulated in Kcnq1 KO mice (Figure 4 and Supplementary  Table 5 , NES À 1.80, Po0.001). This group included a number of genes involved in detoxification, including cytochrome oxidase P450 enzymes and several glutathione S-transferases, Gsta2, Gstm2, Gstm4, Gstm6 and Gstt1. Moreover, in a separate study, 37 deficiency for Muc2 in the mouse intestine resulted in significant increases in the innate immune responders Reg3g and Reg3b, matching our findings in Kcnq1 KO mice. Finally, we found that Areg, an epidermal growth factor receptor pathway gene that was upregulated in both the colon and proximal small intestine of Kcnq1 KO mice, was also upregulated by 410-fold in the colon of Muc2 KO mice (RTC and RJAF, unpublished microarray results) and in the colon of Cftr KO mice (BLNT, personal communication) (see Supplementary Table 6 ).
Loss of Kcnq1 promotes colon organoid development
To investigate a role for Kcnq1 in the intestinal stem cell compartment, we created intestinal organoids from the colons of a group of Apc þ / þ Kcnq1 þ / þ and Kcnq1 À / À age-and gendermatched littermate mice. At days 2-5, organoid growth was monitored and organoid number counted on day 5. Loss of Kcnq1 increased the number of colon organoids by greater than threefold, confirming a potential regulatory effect of Kcnq1 on the intestinal stem cell compartment 22 (Figure 5 ).
KCNQ1 expression is associated with good prognosis in late-stage human CRC On the basis of our finding that deficiency for Kcnq1 drove the progression of intestinal tumors in mice, we tested the hypothesis that low levels of KCNQ1 in human CRC would correlate with a worse prognosis. To this end, we evaluated KCNQ1 protein expression in tissue microarrays containing samples from more than 500 stage IV CRC patients with liver metastases who had undergone hepatic resection. Immunohistochemical staining for KCNQ1 expression was evaluated for 311 patients. Membranes of neoplastic CRC liver metastasis (CRCLM) epithelium were scored for KCNQ1 staining intensity ( Figure 6 ). We found that high KCNQ1 expression was related to improved overall survival (OS) (hazard rate ratio (HRR) 0.64; 95% confidence interval (CI): 0.45-0.92; P ¼ 0.02). Median OS for patients with high KCNQ1 expression was 60 months, whereas patients with low KCNQ1 levels had a median OS of 37 months, indicating a significant 23-month difference in survival (Figure 7 ).
Next, we performed a multivariate analysis to evaluate whether the prognostic value of KCNQ1 protein expression was independent of established prognostic clinicopathological variables, that is, primary tumor-to-liver metastasis interval 412 months, number of liver metastases 41, maximal tumor diameter 45.0 cm, lymph node positivity at the time of diagnosis of the primary tumor and serum carcinoembryonic level 4200 ng/ml. Upon stepwise backward Cox regression analysis with OS as the dependent variable, KCNQ1 expression (HRR, 0.49; 95% : 0.32-0.77; P ¼ 0.002), lymph node positivity at the time of diagnosis of the primary tumor (HRR, 1.64; 95% CI: 1.08-2.48; P ¼ 0.02) and maximal tumor diameter 45.0 cm (HRR, 1.44; 95% CI: 0.96-2.16; P ¼ 0.08) were retained as prognostic variables. Note that the association between maximal tumor diameter and survival was not significant; however, the variable was retained in the model because we only excluded variables when P40.1. 
DISCUSSION
We first identified Kcnq1 as a potential CRC driver gene in our forward genetic screens for GI tract cancer genes. Here, we have followed up with studies using a transgenic mouse model and analysis of human CRC tissues that support a tumor suppressor role for Kcnq1. We demonstrated the tumor suppressor function of Kcnq1 in Apc Min mice, where both hetero-and homozygous inactivation of Kcnq1 resulted in significantly more adenomas and, importantly, progression to adenocarcinoma. This was especially evident in the proximal small intestine. Furthermore, Kcnq1 deficiency caused rectal adenomatous hyperplasia, pyloric tumorigenesis, gastric hyperplasia and pancreatic abnormalities.
Notably, in human CRC that had metastasized to the liver, low KCNQ1 protein expression correlated with significantly lower OS, by almost 2 years, compared to patients with high KCNQ1 expression. These findings suggest that KCNQ1 expression could be a biomarker to help determine eligibility for hepatic resection in CRC patients with liver metastases. In addition, newly developed small molecules that enhance K þ ion channel activity 38, 39 could potentially be used to treat CRC patients with low levels of KCNQ1.
By what mechanism does loss of KCNQ1 influence cancer processes in the GI tract? A promising model is via KCNQ1's functional interactions with CFTR and MUC2. In the healthy intestinal epithelium, KCNQ1 is physiologically linked to the CFTR ion channel, with basolateral export of K þ ions by KCNQ1 providing the electrochemical driving force for apical export of Cl À ions by CFTR. 40 Cftr was identified as a CRC driver gene in two Sleeping Beauty GI tract forward genetic screens, 8, 9 and individuals with cystic fibrosis, caused by inactivating mutations in CFTR, are at increased risk for GI cancers including CRC. 41 To test if common pathways and genes are disrupted by loss of Kcnq1 and Cftr activity, we used GSEA to compare gene sets consisting of genes reported to be up-or downregulated in the small intestine of Cftr KO mice to the entire ranked Kcnq1 expression data set and found significant correlation (Figure 4 ). Genes upregulated in common include several involved in immune responses and inflammation, whereas genes downregulated in common include a subset involved in fatty acid metabolism, in particular lipid oxidation. Further evidence of overlap between KCNQ1 and CFTR was the finding of concordance between KCNQ1 and CFTR expression in RNA Seq analysis of 20 CRC liver metastases ( Supplementary  Figures 7A and B) .
As with Kcnq1 and Cftr, Muc2 deficiency is implicated in CRC. 36 To test if common pathways were disrupted by loss of Kcnq1 and Muc2, we compared gene expression changes in the Kcnq1 KO mice with those reported for Muc2 KO mice. GSEA identified significant overlap in gene expression with genes downregulated in Muc2 KO mice enriched in genes downregulated in Kcnq1 KO mice (Figure 4) . This group included a number of genes involved in detoxification including cytochrome oxidase P450 enzymes and several glutathione S transferases, and genes involved inflammation.
These results point to common pathways (inflammation, lipid metabolism, detoxification and stress responses) disrupted by Kcnq1, Cftr and Muc2 deficiencies. Therefore, we can hypothesize that KCNQ1, like MUC2 and CFTR, may act through one or more of these pathways in preventing cancer in the GI tract. Moreover, precisely defining mechanisms of action for KCNQ1 can lead to its use as a prognostic predictor for CRC patients and potential therapeutic target.
MATERIALS AND METHODS Mice
C57BL/6J mice and C57BL/6J-Apc Min mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). C57BL/6-Kncq1 knockout mice were obtained from Dr Karl Pfeifer (NIH, Bethesda, MD, USA). 14 Details of mouse husbandry are as described previously. 42 The genotype of the Apc and Kcnq1 loci were determined by PCR assays as described previously. 14, 42 Tumor analysis Scoring of GI tumor tissues was performed as described previously. 42 Twosided P-values for tumor counts were determined by use of the Wilcoxon rank-sum test comparing gender-and age-matched classes produced in the same genetic crosses.
Histopathology
Histopathological analysis of tumors and adjoining normal tissue was performed on formalin-fixed paraffin-embedded tissues by an ACVPcertified veterinary pathologist (MGO 0 S) from the University of Minnesota Masonic Cancer Comparative Pathology Shared Resources facility using protocols as described previously. 42 
Organoid culture
Gender-and age-matched littermate C57Bl/6J Kcnq1 þ / þ and Kcnq1 À / À mice were killed between 8 and 12 weeks of age. Colons were removed, cut open and washed in cold phosphate-buffered saline. Colon organoids were then cultured using the protocol of Sato et al., 43 following the plating of 500 crypt bottoms per well in triplicate per sample. Two-sample t-test was used to determine statistical significance.
RNA processing for Illumina bead arrays
Mouse intestinal tissues were removed, opened longitudinally and rinsed in phosphate-buffered saline. Colon tissues were processed in RNAlater (Qiagen, Valencia, CA, USA) as per the manufacturer's protocol. The distal quarter of the proximal quarter of the small intestine was flash frozen in liquid nitrogen. The tissue was then transferred from liquid nitrogen to precooled RNALaterIce (Ambion, Foster City, CA, USA) at À 80 1C for 30 min, and later transferred to À 20 1C for at least 48 h. Immediately before RNA isolation, tissue in either RNALater or RNALaterIce was placed in 2-4 ml of RLT (guanidine thiocyanate buffer)/14.3 M b-mercaptoethanol buffer. The tissue was then homogenized using an IKA Ultra-Turrax T25 digital homogenizer (Fisher Scientific, Waltham, MA, USA). RNA isolation was then conducted using an RNeasy Mini Kit with an additional DNAse Digestion step (Qiagen). RNA sample concentrations were measured using a Nanodrop-1000 Spectrophotometer (Thermo Scientific, Rochester, NY, USA). RNA was stored at À 80 1C.
Illumina bead microarray and data analysis
RNA labeling, microarray hybridization and scanning were performed at the University of Minnesota BioMedical Genomics Center using Illumina MouseWG-6 v.2.0 Expression BeadChips (Illumina, San Diego, CA, USA), according to the manufacturer's instructions. Differential expression of genes was quantified by the moderated t-statistic. Data were analyzed using GeneData Expressionist Software (GeneData Inc., San Francisco, CA, USA); genes that showed statistically significant differences in expression between groups were determined using the two-group t-test and analysis of variance. Gene expression data has been submitted to the Gene Expression Omnibus, and accession number is pending.
qRT-PCR
Quantitative RT-PCR was performed as described previously. 12 Significant differences in expression between groups were determined using the two-group t-test.
List of primers used
All primers were designed using Primer-BLAST (National Center for Biotechnology Information) and obtained from Integrated DNA Technologies.
Mouse primers
Ang4: forward, 5 0 -AGCACACAGCTAGACTCGTCCC-3 0 ; reverse, 5 0 -ACCAGAC CCAGCACGAAGACC-3 0 ; Areg: forward, 5 0 -GGTCTTAGGCTCAGGCCATTA-3 0 ; reverse, 5 0 -CGCTTATGGTGGAAACCTCTC-3 0 ; Cd55: forward, 5 0 -GGGGCTATG ATCCGTGGGCG-3 0 ; reverse, 5 0 -TGCCCAAGATTGGCCTGGCA-3 0 ; Clca3: forward, 5 0 -CCACACCAAAACGAGAAGGC-3 0 ; reverse, 5 0 -TGCTTCGGAGATTG CATCGT-3 0 ; Clca4: forward, 5 0 -ACATGGACCGGCCTTTCTAC-3 0 ; reverse, 5 0 -CG ACATCTCCTCGACACACA-3 0 ; Clca6: forward, 5 0 -GTTCAATCAGAAAAGGCTT CCA-3 0 ; reverse, 5 0 -ACTTCCCAAGTGCTTCTGTAATTG-3 0 ; Gstk1: forward, 5 0 -TGGATGCGTGTATGGTCTCG-3 0 ; reverse, 5 0 -CAGAAAGTGTTGGGCTTGCG-3 0 ; Egr1: forward, 5 0 -CCTCAAGGGGAGCCGAGCG-3 0 ; reverse, 5 0 -AACCGAGT CGTTTGGCTGGG-3 0 ; Fos: forward, 5 0 -CGGGTTTCAACGCCGACTA-3 0 ; reverse, 5 0 -TTGGCACTAGAGACGGACAGA-3 0 ; Id1: forward, 5 0 -CTCAGCACCCTGAAC GGCGA-3 0 ; reverse, 5 0 -CATCTGGTCCCTCAGTGCGCC-3 0 ; Muc2: forward, 5 0 -AACGATGCCTACACCAAGGTC-3 0 ; reverse, 5 0 -ACTGAACTGTATGCCTTCC TCA-3 0 ; Muc3: forward, 5 0 -CACTACCACCCCAGCACCTA-3 0 ; reverse, 5 0 -GCCT CCATTCTCGCAGTTGA-3 0 ; Muc13: forward, 5 0 -TTTGGCTACAGCGGGAT GAA-3 0 ; reverse, 5 0 -TCTTTGACCTCGCAGAGACG-3 0 ; Mt1: forward, 5 0 -AAAC CCTTTGCGCCCGGACT-3 0 ; reverse, 5 0 -AGCAGGAGCAGTTGGGGTCC-3 0 ; Pim3: forward, 5 0 -GCTCATCGACTTCGGCTCGGG-3 0 ; reverse, 5 0 -AGTGGCAGACCGC CCGTGATA-3 0 ; and Retnlb: forward, 5 0 -AAGCCTACACTGTGTTTCCTTTT-3 0 ; reverse, 5 0 -GCTTCCTTGATCCTTTGATCCAC-3 0 .
Pathway analysis
GSEA. GSEA v.2.0, http://www.broad.mit.edu/gsea/. 24, 44 Gene sets analyzed were obtained from published reports and the National Center for Biotechnology Information Gene Expression Omnibus database. GSEA compared the entire ranked Kcnq1 proximal small intestine KO expression data set to Cftr KO 25 (twofold change in expression, tp0.05) and Muc2 KO 36 (1.5-fold change in the duodenum at 3 or 6 months of age).
IPA.
Genes showing a 1.5-fold change in expression in whole colon (N ¼ 89) and proximal small intestine (N ¼ 345) microarrays were analyzed using IPA. 23 
Tissue microarrays
Patient study population. Patients who underwent liver resection with curative intent, sometimes with addition of RFA, in one of the seven Dutch hospitals affiliated with the DeCoDe PET group were identified by crossreferencing surgery and pathology databases using Dutch MeSH terms for 'colon', 'rectum', 'carcinoma', 'adenocarcinoma', 'colorectal neoplasms', 'liver', 'neoplasm metastasis' and '(hemi)hepatectomy'. Clinicopathological data from 507 patients that were operated on between 1990 and 2010 were extracted from these databases (see Supplementary Table 7 ; a manuscript describing the patient population in more detail is in preparation). Formalin-fixed paraffin-embedded tissue specimens were collected from one CRCLM sample and an adjacent control liver sample. Only specimens of patients with histologically confirmed CRCLM were included in the study, whereas tissue samples of patients with multiple primary tumors were excluded. Collection, storage and use of clinicopathological data and tissue specimens were performed in compliance with the 'Code for Proper Secondary Use of Human Tissue in The Netherlands', and approved in protocol 2011-03 of the Department of Pathology. 45 Tissue microarrays. A total of 21 tissue microarrays (TMAs) were generated as described previously. 46, 47 In brief, three tissue core biopsies of 0.6 mm in diameter were punched from morphologically representative areas of all formalin-fixed paraffin-embedded donor blocks, and transferred into TMA recipient paraffin blocks using the 3DHISTECH TMA Master (v.1.14, 3DHISTECH Ltd, Budapest, Hungary).
Immunohistochemistry. Four-micrometer sections of TMAs were mounted on glass slides, deparaffinized by xylene and rehydrated with a decreasing alcohol series. Staining for KCNQ1 was performed upon antigen retrieval by microwave heating in citric acid (10 mM, pH 6.0) and endogenous peroxidase neutralization in 0.3% hydrogen peroxide in methanol for 25 min. The primary rabbit polyclonal antibody directed against human KCNQ1 (sc-20816; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was incubated overnight at a 1:200 dilution at 4 1C, followed by incubation with anti-rabbit secondary antibodies for 30 min at room temperature (Envision Plus; Dako, Heverlee, Belgium). Secondary antibodies were visualized by liquid diaminobenzidine substrate chromogen system. Slides were counterstained with Mayer's hematoxylin. Staining of formalin-fixed paraffin-embedded colon tissue was used as a positive control, and incubation without primary antibody as a negative control.
Evaluation of KCNQ1 protein expression. Immunohistochemical stainings were digitally captured using the Mirax slide scanner system equipped with a Â 20 objective with a numerical aperture of 0.75 (Carl Zeiss BV, Sliedrecht, The Netherlands) and a Sony DFW-X710 Fire Wire 1/3 in-type progressive SCAN IT CCD (pixel size 4.65 Â 4.65 mm 2 ). Actual scan resolution at Â 20 was 0.23 mm. Computer monitors were calibrated using Spyder2PRO software (v.1.0-16; Pantone Colorvision, Regensdorf, Switzerland). TMA core biopsies were scored for intensity of KCNQ1 protein expression on membranes of neoplastic epithelial cells (categories negative, weak, moderate, strong) using dedicated TMA scoring software (v.1.14.25.1; 3DHISTECH Ltd). For facilitating scoring, a chart with visual analogue scales of staining patterns was used. Intensity scores were dichotomized into low and high KCNQ1 intensities using receiver operating characteristic curve analysis. 48 Statistical analysis of TMAs. OS was defined as the time in months after surgery until death in a follow-up period of 10 years. Patients were excluded from analysis if OS o2 months (n ¼ 72), if OS or survival status were unknown (n ¼ 36) or if tissue cores could not be evaluated for technical reasons (n ¼ 88). The relation between KCNQ1 expression and survival was studied using Kaplan-Meier curves and tested using log-rank statistics. HRR was calculated using Cox regression. Multivariate analysis was performed by inclusion of KCNQ1 protein expression in a proportional hazards (Cox regression) analysis together with established prognostic clinicopathological variables combined in the clinical risk score as defined by Fong et al., 49 primary tumor-to-liver metastasis interval 412 months, number of liver metastases 41, maximal tumor diameter 45.0 cm, lymph node positivity at the time of diagnosis of the primary tumor, serum carcinoembryonic level 4200 ng/ml. Stepwise backward regression was used to exclude variables from the model when P40.1. All statistical tests were two-sided and executed using IBM SPSS Statistics 20.0 software (SPSS Inc., Chicago, IL, USA). P-values o0.05 were considered significant.
